NLRP3 and COVID-19: In this line, a recent study unveiled a spontaneous NLRP3 inflammasome over-activation and IL-1β secretion in monocytes from severe COVID-19 patients that could be reverted by treating the patients with the IL-1 receptors blocker anakinra [59].